Colorado 'sexual wellness' firm moving to bigger exchange after stock split
An Arapahoe County company that specializes in treating low testosterone in men and diagnosing male infertility is moving its shares to the Nasdaq stock exchange. Aytu BioScience Inc., which engineered a 1-for-20 reverse split in August in an effort to make the move from the over-the-counter bulletin board exchange, said its shares ("AYTU") will begin trading on the Nasdaq exchange on Friday. "To augment our operational progress, we believe that listing on Nasdaq will help the company further diversify…
Authors: Fung C, Dinh P, Ardeshir-Rouhani-Fard S, Schaffer K, Fossa SD, Travis LB Abstract Testicular cancer has become the paradigm of adult-onset cancer survivorship, due to the young age at diagnosis and 10-year relative survival of 95%. This clinical review presents the current status of various treatment-related complications experienced by long-term testicular cancer survivors (TCS) free of disease for 5 or more years after primary treatment. Cardiovascular disease and second malignant neoplasms represent the most common potentially life-threatening late effects. Other long-term adverse outcomes include neuro...
Abstract Recent evidences suggest that hypogonadism is an important risk factor for lower urinary tract symptoms and benign prostatic hyperplasia. Several papers have discussed the role of chronic inflammation in the development of BPH, which may be modulated by the hypogonadal state. Soluble urokinase-type plasminogen activator receptor (suPAR), known protein marker of systemic inflammation, can be assayed in the seminal plasma and represents a reliable and sensitive marker of inflammation for the male accessory gland inflammation (MAGI). The aim of this study has been to investigate if seminal suPAR is elevated ...
Testosterone deficiency has been linked to several adverse health outcomes - including cardiovascular disease, erectile dysfunction, and metabolic syndrome. Recent data has suggested that abnormal sleep quality may result in lower testosterone levels. Using the 2011- 2012 National Health and Nutrition Surveys (NHANES) we assessed the effect of self-reported sleep patterns on serum testosterone while controlling for physical activity levels, co-morbidities, and baseline demographics.
Excess nitrosative stress can lead to erectile dysfunction and infertility. We tested the hypothesis that nitrosative stress affects the hypothalamus-pituitary-gonadal axis leading to secondary hypogonadism.
Sertoli cells thrive in an environment of high testosterone concentrations. Therefore, when subjected to low levels of testosterone, from any cause, abnormal spermatogenesis may occur. We performed a secondary analysis of a large, prospective clinical trial of couples with unexplained infertility to analyze whether sperm quality and pregnancy/live birth (LB) rates were associated with low total testosterone (TT).
The primary goal in treatment of idiopathic hypogonadotropic hypogonadism (IHH) is to induce masculinization and spermatogenesis. Exogeneous testosterone (T) can induce masculinization but not spermatogenesis and rather may be associated with impaired spermatogenesis. This retrospective study aims to determine whether concomitant T based on HCG treatment show significantly harmful impacts on spermatogenesis in IHH patients compared HCG alone.
Follicle-stimulating hormone (FSH) is a gonadotropin produced by the anterior pituitary gland and is trophic to the sertoli cells to maintain spermatogenesis. FSH is prescribed to men with hypogonadotropic hypogonadism (congenital or acquired) seeking fertility. Commercially available FSH, branded Gonal-F (B-FSH), is often cost prohibitive for patients, leading to the recent development of compounded alternatives. Here we compare the clinical and cost-effectiveness of B-FSH with compounded FSH (C-FSH).
Exogenous testosterone supplementation can be used to treat low testosterone; however, it has several adverse effects including infertility due to negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis. We evaluated the feasibility of subcutaneously autografting Leydig stem cells (LSC) in combination with Sertoli and myoid cells to increase testosterone. Furthermore, we evaluated the mechanism essential for survival of LSC in extra-testicular milieu.
Male infertility has multiple etiologies, many of which are treatable. Recent reports have demonstrated the deleterious impact of obesity on male fertility. Obese men often experience hypogonadism, typically secondary to hyperestrogenemia. This is presumably due to increased aromatase activity in body fat, resulting in impaired hormone and sperm production. The aim of this study is to investigate the effect of anastrazole on semen profiles in infertile men with hyperestrogenemia.
Clomiphene citrate (CC) is commonly used in the treatment of male hypogonadism/infertility as an off-label medication. CC can cause increased estradiol (E) levels and decreased testosterone to estradiol ratio (T/E) in some patients necessitating addition of aromatase inhibitors such as Anastrozole (AZ) to optimize E and T/E levels. Little data is available on the conversion rate from CC monotherapy to combination CC+AZ therapy and the predictors of this conversion.